Set your IND up for success by getting FDA-accepted monoclonality assurance in just days.
Replace 8-12 weeks of challenging well plate steps with Opto CLD on the Beacon optofluidic system. Screen thousands of clones in parallel with advanced in-process imaging and automation and increase capacity to up to 50 campaigns.
Select top clones for even non-traditional antibody molecules, like bispecifics.
The Opto CLD Workflow selects top clones by measuring growth and titers over multiple days of on-chip culture. SpotLight™ assays enable quantification of both traditional and non-traditional antibodies, such as Fc-engineered mAbs, bispecifics, and multispecifics.
Get to production faster with Opto™ Assure for early manufacturability assessment.
Opto™ Assure minimizes risk of costly late stage failures by identifying clones early on that secrete product with high yield and desired quality. Opto Assure assay for aggregation enables direct detection of product aggregates within days of single cell cloning. This lets you confidently identify and select clones that secrete high-quality complex molecules and develop better production cell lines faster.
The Berkeley Lights Opto CLD workflow enables in-line controls to measure clonality during clone recovery. After recovery of each clone, media is flushed into “blank” wells to detect any residual cells. Expand >90% of selected clones from the Beacon system when recovered into 96-well plates, with >99% monoclonality assurance – which is equivalent to four rounds of limiting dilution!
The Beacon system’s optofluidic chip technology and integrated imaging provide direct evidence of >99% monoclonality, without manual effort and uncertainty of traditional methods. Learn how the Opto CLD workflow provides superior cloning technology and in-process quality controls for definitive evidence of monoclonality to support regulatory approvals.
Spotlight assay: Simultaneous, quantitative antibody titer measurements on thousands of clones (LEFT). Clones selected based on titer measurements on the Beacon system had 1.5–3-fold higher titers than clones selected using traditional clone picking technology when scaled up to shake flask fed-batch cultures (RIGHT). ©2019 Catalent, Inc. All rights reserved.
Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.
Find our how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development and allows CDMOs to scale operations and drive new business.
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.